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346Impact of hospital volume and type on outcomes
of open and endovascular repair of descending
thoracic aneurysms in the United States Medicare
population
Virendra I. Patel, MD, MPH, Shankha Mukhopadhyay, MS, Emel Ergul, MS, Nathan Aranson, MD,
Mark F. Conrad, MD, Glenn M. LaMuraglia, MD, Christopher J. Kwolek, MD, and
Richard P. Cambria, MD, Boston, Mass
Objective: Favorable outcomes of thoracic endovascular aortic repair (TEVAR) compared with open repair for descending
thoracic aortic aneurysms (DTAs) have led to increasing TEVAR use. We evaluated the effect of case volume and hospital
teaching status on clinical outcomes of intact DTA repair.
Methods: The Medicare Provider Analysis and Review (MEDPAR) data set (2004 to 2007) was queried to identify open
repair or TEVAR for DTA. Hospitals were stratiﬁed by DTA volume into high volume (HV; $8 cases/y) or low volume
(LV; <8 cases/y) and teaching or nonteaching. The effect of hospital variables on the primary study end point of 30-day
mortality and secondary end points of 30-day complications and long-term survival after open repair and TEVAR DTA
repair were studied using univariate testing, multivariable regression modeling, Kaplan-Meier survival analysis, and Cox
proportional hazards regression modeling.
Results: We identiﬁed 763 hospitals performing 3554 open repairs and 3517 TEVARs. Overall DTA repair increased
(P < .01) from 1375 in 2004 to 1987 in 2007. The proportion of hospitals performing open repair signiﬁcantly decreased
from 95% in 2004 to 57% in 2007 (P < .01), whereas those performing TEVAR increased (P < .01) from 24% to 76%.
Overall repair type shifted from open (74% in 2004, the year before initial commercial availability of TEVAR) to TEVAR
(39% open in 2007; P < .01). The fraction of open repairs at LV hospitals decreased from 56% in 2004 to 44% in 2007
(P < .01), whereas TEVAR increased from 24% in 2004 to 51% in 2007 (P < .01). Overall mortality during the study
interval for open repair was 15% at LV hospitals vs 11% at HV hospitals (P < .01), whereas TEVAR mortality was similar,
at 3.9% in LV vs 5.5% in HV hospitals (P [ .43). LV was independently associated with increased mortality after open
repair (odds ratio, 1.4; 95% conﬁdence interval, 1.1L1.8; P < .01) but not after TEVAR. There was no independent effect
of hospital teaching status on mortality or complications after open repair or TEVAR repair.
Conclusions: The total number of DTA repairs has signiﬁcantly increased. Operative mortality for TEVAR is indepen-
dent of hospital volume and type, whereas mortality after open surgery is lower at HV hospitals, suggesting that
TEVAR can be safely performed across a spectrum of hospitals, whereas open surgery should be performed only at HV
hospitals. (J Vasc Surg 2013;58:346-54.)The feasibility of thoracic endovascular aortic repair In addition, the operative mortality and morbidity
(TEVAR) for descending thoracic aortic aneurysms
(DTAs) was ﬁrst reported by Dake et al1 in 1994. Subse-
quent industry-sponsored comparative trials have shown
that TEVAR is associated with reduced perioperative
morbidity and mortality compared with open DTA
repair.2-5 Results from these device trials led to United
States Food and Drug Administration (FDA) approval for
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device registries9,10 have further supported the ﬁndings
from the comparative trials.2-4 This has led to widespread
acceptance of TEVAR for the management of DTA in
contemporary practice. As such, in the years after FDA
approval, TEVAR has supplanted open surgical repair in
most patients with an anatomically suitable DTA.11-13
Previous publications have only reported the effect of
hospital volume on outcomes of open DTA repair,14
without addressing the effect of hospital teaching status
on outcomes. Despite the widespread use of TEVAR, the
effects of hospital type and volume on outcomes of DTA
repair in the age of TEVAR are as yet unknown. The
goal of this study was to evaluate the effects of hospital
teaching status and hospital volume on operative mortality
and outcomes after DTA repair.
METHODS
Data set. This study evaluated the effects of hospital type
and procedural volume on outcomes of DTA repair using
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data set from 2004 to 2007. The MEDPAR ﬁle contains
Part A claims data for all Medicare admissions and
includes demographic information, admission Interna-
tional Classiﬁcation of Diseases, 9th Revision (ICD-9)
codes, procedural ICD-9 codes, discharge data, and
hospital cost data. Linkage with the Medicare Denomi-
nator and Vital Statistics ﬁles provided geographic and
survival information for the study cohort. The MEDPAR
data set was queried to identify all patients with an ICD-9
diagnosis of intact DTA (441.2) and a procedure code
for open repair (38.35 or 38.45dreplacement of thorac-
ic vessel with repair/anastomosis) or TEVAR repair
(39.73dendovascular implant graft thoracic aorta; 39.79
was used for years before 39.73 was available). The study
excluded patients with ruptured thoracic aneurysms
(441.1, 441.5), thoracoabdominal aneurysms (441.6,
ruptured; 441.7, intact), thoracic aortic dissection (441),
those with a diagnosis of ascending aortic aneurysms,
those undergoing concomitant coronary or cardiac valve
procedures, and those treated with cardioplegia. Patients
were categorized by ICD-9 diagnosis as having under-
gone thoracic aortic replacement or repair, without
anatomic distinction for arch or DTA disease. Given the
use of hypothermic circulatory arrest (HCA) for all aortic
arch reconstruction and its very limited use for DTA
repair at some centers, patients undergoing HCA were
excluded.
Study design. This retrospective study evaluated the
effect of hospital teaching status (teaching vs nonteaching)
and hospital volume (high volume [HV] vs low volume
[LV]) on the primary outcome measure of 30-day
mortality in patients undergoing open or TEVAR repair
of DTA. Secondary outcome measures included any
complication and long-term survival. Hospital teaching
status was as deﬁned by the MEDPAR data set (yes or no).
Hospitals performing TEVAR and open DTA were
stratiﬁed as HV or LV according to annual volume. Those
hospitals performing >50th percentile of all DTA proce-
dures were deﬁned as HV hospitals. Annual case volume
at HV hospitals exceeded eight DTA procedures per year
(mean, 22 6 16/y), whereas LV hospitals performed eight
or fewer procedures annually (mean, 2 6 1/y). Additional
thresholds to deﬁne HV were evaluated without affecting
study conclusions; therefore, the 50th percentile was
chosen for ﬁnal analysis.
Comorbidities were identiﬁed using ICD-9 codes for dia-
betes mellitus (250.0-250.9), hypertension (401.0-405.9),
chronic obstructive pulmonary disease (490.0-496.0), ische-
mic heart disease (410.0-414.9), cerebrovascular disease
(430.0-438.0), and peripheral arterial disease (440.0-
440.9, 443.0-443.9). Complications were similarly identi-
ﬁed using ICD-9 codes.
Data analysis. Categoric variables are presented as
absolute number and percentages, with continuous data
presented as mean values 6 standard deviation. Univariate
analysis was performed by using the c2 or the Fisher exact
test for discrete variables, the t-test with equal variancesfor normally distributed continuous variables, and the
Wilcoxon rank-sum test for non-normally distributed
continuous and ordinal variables. Analyses for trends across
time were performed using a c2 trend test. Multivariable
regression analyses were performed to identify independent
predictors of perioperative (30-day) death or any compli-
cation. Kaplan-Meier analysis was used to assess actuarial
survival, with differences between the areas under the
curves determined by the log-rank test. Proportional
hazards regression analysis was performed to evaluate for
risk-adjusted effect of hospital type on late survival. P < .05
was considered signiﬁcant. All statistical analysis was per-
formed using SAS 9.2 software (SAS Institute, Cary, NC).
RESULTS
Our study consisted of 7071 patients, 3554 open and
3517 TEVAR, who underwent DTA repair at 763 hospi-
tals during the study period. The total annual number of
DTA repairs signiﬁcantly increased, from 1375 in 2004
to 1987 in 2007 (P < .001), driven mainly by a signiﬁcant
increase in TEVAR with a signiﬁcant decrease in open
repair (Table I). By 2007, the proportion of open proce-
dures had decreased to 38% compared with 74% in 2004.
A signiﬁcant increase occurred in the number of hospitals,
teaching hospitals, nonteaching hospitals, and LV hospitals
performing DTA repair over time (Table II), whereas the
number of HV hospitals remained stable. The proportion
of hospitals performing open DTA repair signiﬁcantly
decreased, but the number of hospitals performing TEVAR
signiﬁcantly increased (Table II). This trend was experi-
enced by all hospital types, which increasingly adopted
TEVAR over open repair.
The proportions of open DTA repairs performed at
teaching and nonteaching hospitals remained stable during
the study period, whereas open cases shifted from LV to
HV hospitals (Table III, A). Similarly, the proportions of
TEVAR cases performed at teaching and nonteaching
hospitals remained stable (Table III, B). TEVAR cases
shifted from HV hospitals to LV hospitals during the study
period, with a sevenfold increase in the number of TEVARs
performed at LV hospitals, from 84 in 2004 to 618 in 2007
(Table III, B).
Demographic and clinical features of patients under-
going open or TEVAR repair stratiﬁed by hospital teaching
status and volume are presented in Table IV. Univariate
analysis shows that patients treated at teaching hospitals
were younger, independent of repair type, and those
undergoing TEVAR were less likely to be white, have coro-
nary artery disease (CAD), and peripheral vascular disease
(PVD) than at nonteaching hospitals (Table IV, B).
Patients undergoing open repair at HV centers were
more likely to be white and have CAD, PVD, and cerebro-
vascular disease (Table IV, A) than those treated at LV
hospitals. The rest of the clinical and demographic features
were similar across hospital type and volume strata
(Table IV) by univariate analyses. HV hospitals were
more likely to be teaching hospitals (93% HV vs 66% LV;
P < .001).
Table II. Proportions of hospitals performing
descending thoracic aneurysm repair over time
Hospital type Total
Year
P2004 2005 2006 2007
All hospitals, No. 763 359 382 475 496 <.0001
Open, % 95 82 62 57 <.0001
TEVAR, % 24 50 73 76 <.0001
Teaching, No. 510 270 284 348 357 <.0001
Open, % 95 85 63 61 <.0001
TEVAR, % 28 52 78 79 <.0001
Nonteaching, No. 253 89 98 127 138 <.0001
Open, % 97 71 60 48 <.0001
TEVAR, % 10 44 61 68 <.0001
Low-volume, No. 723 319 343 436 456 <.0001
Open, % 95 80 59 54 <.0001
TEVAR, % 17 44 71 74 <.0001
High-volume, No. 40 40 39 39 40 .38
Open, % 100 100 97 97 .048
TEVAR, % 75 97 100 100 <.0001
TEVAR, Thoracic endovascular aortic repair.
Table I. Variation in descending thoracic aneurysm













All 7071 1375 1697 2013 1987
Open 3554 1024 924 817 746
TEVAR 3517 351 773 1196 1231
TEVAR, Thoracic endovascular aortic repair.
aP < .001 for all variables.
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stratiﬁed by hospital type are presented in Table V. Despite
baseline clinical and demographic differences (as shown in
Table IV), risk-adjusted (age, sex, race, hypertension, dia-
betes, CAD, PVD, chronic kidney disease, hospital volume,
and teaching status) multivariable modeling showed no
independent effect of teaching status on operative mortality
for open (odds ratio [OR], 1.28; 95% conﬁdence interval
[CI], 0.9-1.8; P ¼ .16) or TEVAR (OR, 1.24; 95% CI:
0.8-1.9; P ¼ .37) repair. Multivariable analysis also showed
that operative mortality was reduced when open surgery
(OR, 0.72; 95% CI, 0.6-0.9; P < .01) was performed at
HV hospitals; however, operative mortality after TEVAR
at HV hospitals (OR, 0.9; 95% CI, 0.1-1.3; P ¼ .76) was
similar to that at LV hospitals. Risk-adjusted complication
rates were similar for open (OR, 1.1; 95% CI, 0.9-1.4;
P ¼ .3) and TEVAR (OR, 1.3; 95% CI, 0.9-1.6; P ¼ .06)
when performed at teaching hospitals. The risk of complica-
tions after open repair at HV hospitals (OR, 1.1; 95% CI,
0.9-1.3; P ¼ .24) was similar to that at LV hospitals.
Complications after TEVAR were higher at HV hospitals
(OR, 1.5; 95% CI, 1.3-1.8; P < .01). Multivariablepredictors of increased 30-day mortality and complications
are presented in Tables VI, A and B, respectively.
The long-term survival of patients undergoing open or
TEVAR repair was similar (log-rank, P > .05) at teaching
and nonteaching hospitals (Table VII). The long-term
survival of patients undergoing TEVAR was similar (log-
rank P ¼ .7) at LV and HV hospitals (Table VII), whereas
the long-term survival of patients undergoing open repair
(Fig) was higher (log-rank, P < .05) at HV hospitals.
Proportional hazards regression showed that HV hospitals
were associated with improved risk-adjusted (baseline clin-
ical features) long-term survival (hazard ratio [HR], 0.82;
95% CI, 0.73-0.92; P < .01) after open surgery, whereas
teaching hospitals were associated with lower long-term
survival (HR, 1.3; 95% CI, 1.1-1.6; P ¼ .01). Patients
undergoing TEVAR had similar long-term survival hazards
independent of hospital volume (HR 1.03 for HV; 95% CI,
0.91-1 2; P ¼ .6) or teaching status (HR 0.9 for teaching;
95% CI, 0.783-1.1; P ¼ .2). Multivariable predictors of
increased late mortality are presented in Table VIII.
DISCUSSION
Since FDA approval of the ﬁrst commercially available
thoracic stent graft in 2005, there has been a signiﬁcant
increase in the use of TEVAR for repair of DTA. This
has resulted in expanding indications11 and application of
TEVAR to higher-risk patients for whom open surgery
was previously considered prohibitive.15-17 Our previous
work12 showed that in #3 years (2005 to 2007) of FDA
approval, there was a signiﬁcant expansion in TEVAR use
and increasing application of TEVAR for acute aortic
pathologies, all of which were off-label use.
This report furthers that effort and shows that there has
been not only a rapid expansion in TEVAR use but also an
increasing adoption of TEVAR across all hospital types
independent of teaching status or hospital volume. Most
dramatic has been the consistent annual increase in
TEVAR procedures at LV hospitals reﬂecting an increasing
number of new hospitals incorporating DTA repair with
TEVAR into their scope of practice. Increased commercial
accessibility of TEVAR devices, relative ease of use and
deployment, and expanding endovascular experience has
likely contributed to this expansion.
Concomitantly, the absolute numbers and proportions
of hospitals performing open DTA repair have decreased
independent of hospital volume and type. This likely relates
to the signiﬁcant resource utilization by health care
systems, the signiﬁcant physiologic and recovery impact
to patients, and the technical challenges required of
surgeons involved in open DTA repair. The small annual
decreases in open procedures at HV hospitals coupled
with the consistent increases in TEVAR at all hospital types
and the increasing number of annual DTA repairs suggests
an increasing application of TEVAR to an expanding pop-
ulation of patients, without signiﬁcant increases in referral
to HV centers, even for open surgery.
The proportion of open procedures performed at HV
hospitals has steadily increased, whereas the absolute





(n ¼ 3554), %
2004
(n ¼ 1023), %
2005
(n ¼ 924), %)
2006
(n ¼ 833), %
2007
(n ¼ 774), %
Teaching 89 88 89 89 89 .86
Nonteaching 11 12 11 11 11 .86
Low-volume 49 56 49 46 44 <.001
High-volume 51 44 51 54 56 <.001





(n ¼ 3554), %
2004
(n ¼ 1023), %
2005
(n ¼ 924), %
2006
(n ¼ 833), %
2007
(n ¼ 774), %
Teaching 85 87 87 85 84 .31
Nonteaching 15 13 13 15 16 .31
Low-volume 46 24 40 51 51 <.001
High-volume 54 76 60 49 49 <.001












(n ¼ 1772) P
Age, years 72 6 8.0 73 6 8.1 74 6 7.7 .002 72 6 7.9 72 6 8.1 .75
Sex .93 .27
Male 50 50.1 50 49 51
Female 50 49.9 50 51 49
Race .25 .018
White 88 87 89 86 89
Other 12 13 11 14 11
Comorbidities
HTN 59 58.4 62 .23 57 60 .096
DM 8.3 8.2 9.2 .53 9 7.7 .16
CAD 26 26 25 .51 24 28 .003
COPD 36 36 36 .81 35 37 .23
CVD 5 4.9 5.3 .72 5.5 4.5 .15
PVD 12 12 7.9 .014 7.6 16 <.001
CKD 4.8 5.2 1.5 .001 3.4 6.2 .0001
CAD, Coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; DM, diabetes
mellitus; HTN, hypertension; PVD, peripheral vascular disease.
aContinuous data are shown as mean 6 standard deviation and categoric data as percentage.
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slightly decreased. This suggests some degree of regionali-
zation as LV hospitals abandon open surgery in favor of
TEVAR; however, the number of actual open DTA repairs
performed at LV hospitals remains substantial (w700 cases
in 2006 and 2007), which has mortality and survival
implications.
Several publications have previously deﬁned the
importance of hospital volume on outcomes of complex
aortic procedures. Cowan et al,18 using the National
Inpatient Sample (NIS), noted that high hospital volume
was an independent predictor of lower hospital mortalitycompared with medium-volume or LV hospitals perform-
ing thoracoabdominal aneurysm repair. More recently,
using the same database, Schermerhorn et al14 similarly
noted the importance of hospital volume on outcomes of
open DTA repair. In this series (1988 to 2003), predating
commercial availability of TEVAR, LV (1 DTA repair/y)
or medium-volume (2 to 3/y) hospitals were indepen-
dently associated with increased hospital mortality (OR,
1.3; 95% CI, 1.1-1.7; P < .05) for open DTA repair.14
Unlike these reports, which deﬁned volume as low,
medium, or high according to volume terciles, we deﬁned
hospital volume as HV or LV by the 50th percentile in












(n ¼ 1758) P
Age, years 75 6 7.8 75 6 7.9 76 6 7.3 .018 75 6 7.7 75 6 7.9 .94
Sex .82 .35
Male 58 58 58 57 59
Female 42 42 42 43 42
Race <.0001 .84
White 86 85 92 86 86
Other 14 15 7.8 14 14
Comorbidities
HTN 70 71 68 .14 72 69 .053
DM 13 13 11 .11 13 13 .81
CAD 34 33 41 .0005 35 33 .24
COPD 41 41 42 .72 40 42 .36
CVD 4.5 4.5 4.6 .88 4.6 4.4 .81
PVD 16 15 19 .023 16 15 .86
CKD 9.9 10 9.1 .52 10 9.5 .43
CAD, Coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; DM, diabetes
mellitus; HTN, hypertension; PVD, peripheral vascular disease.
aContinuous data are shown as mean 6 standard deviation and categoric data as percentage.
Table V. A, Clinical outcomes after open aortic repair by hospital type
Variable
All hospitals
(N ¼ 3554), %
Teaching
(n ¼ 3161), %
Nonteaching
(n ¼ 393), % P
Low-volume
(n ¼ 1782), %
High-volume
(n ¼ 1772), % P
30-day death 12 12 12 .94 15 11 .0048
Any complication 50 50 46 .084 47 51 .044
Bleeding 17 17 14 .19 16 17 .5
Cardiac 13 13 10 .14 12 13 .54
Infectious 7.1 7.4 4.8 .065 5.9 7.5 .12
Pulmonary 23 23 19 .078 21 23 .17
Graft 1.5 1.5 1 .41 1 1.6 .21
Renal failure 19 19 16 .063 17 20 .18
Table V. B, Clinical outcomes after endovascular aortic repair by hospital type
Variable
All hospitals
(N ¼ 3517), %
Teaching
(n ¼ 3001), %
Nonteaching
(n ¼ 516), % P
Low-volume
(n ¼ 1759), %
High-volume
(n ¼ 1758), % P
30-day death 5.2 5.3 4.5 .42 3.9 5.5 .09
Any complication 30 30 25 .0094 24 31 .0004
Bleeding 13 13 11 .076 11 13 .19
Cardiac 4.9 5.1 3.9 .25 3.2 5.3 .019
Infectious 3.6 3.6 3.7 .95 2.9 3.8 .24
Pulmonary 7.4 7.5 6.8 .55 6.1 7.7 .13
Graft 4.8 5 3.5 .14 3 5.2 .016
Renal failure 6.6 6.7 6.2 .69 5.3 6.9 .14
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investigators.19,20 Despite differences in methodology, our
threshold for HV (>8 procedures/y) was similar to the
Cowan et al18 report (median 7 procedures/y). In addi-
tion, our conclusions regarding the effect of hospital
volume are also similar, because open DTA repair at HV
hospitals was associated with lower risk-adjusted operativemortality (OR, 0.56; 95% CI, 0.4-0.7; P < .01). Our study
has the additional advantage of perioperative mortality data
beyond the initial hospitalization and long-term survival
analysis, both of which are a limitation of the NIS data set.
Our results showing improved long-term survival in
patients undergoing open DTA repair at HV hospitals
likely reﬂect the perioperative mortality beneﬁt afforded
Table VI. A, Multivariable predictors of increased
30-day mortality
Variable OR (95 % CI) P
Open repair
Age, per year 1.04 (1.02-1.05) <.01
Female sex 1.3 (1.06-1.6) .01
Low volume 1.4 (1.1-1.8) <.01
Nonwhite race 1.6 (1.1-2.1) <.01
Chronic kidney disease 1.8 (1.2-2.8) <.01
Cerebrovascular disease 2.7 (1.9-3.9) <.01
TEVAR
Cerebrovascular disease 3 (1.8-4.9) <.01
CI, Conﬁdence interval; OR, odds ratio; TEVAR, thoracic endovascular
aortic repair.
Table VI. B, Multivariable predictors of increased
30-day complications
Variable OR (95 % CI) P
Open repair
Age, per year 1.02 (1.01-1.03) <.01
Female sex 1.2 (1.02-1.4) .01
Nonwhite race 1.4 (1.2-1.8) <.01
Chronic kidney disease 1.6 (1.1-2.4) <.01
TEVAR
Age, per year 1.02 (1.01-1.03) <.01
High volume 1.5 (1.3-1.8) <.01
Female gender 1.5 (1.3-1.7) .01
Chronic kidney disease 1.8 (1.4-2.3) <.01
CI, Conﬁdence interval; OR, odds ratio; TEVAR, thoracic endovascular
aortic repair.
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diverge or converge long term. Although not speciﬁcally
studied, this implies open surgical repair in similar-risk
patients at LV and HV centers, and therefore, a health
care systems-based (operative and postoperative) advantage
at HV centers. The importance of the long-lasting effect
of hospital volume on patient survival has additional
relevance.
Goodney et al21 recently reported that patients under-
going open DTA repair had improved long-term survival
compared with patients undergoing TEVAR, with loss of
perioperative survival advantage of TEVAR by 1 year
(87% open vs 82% TEVAR; log-rank, P ¼ .001). Further-
more, this advantage of open repair was more pronounced
in risk-adjusted and propensity-matched cohorts. Our
study did not formally evaluate late outcomes comparing
open and endovascular management of thoracic aneu-
rysms; however, similar to Goodney et al,21 we noted an
early (1-year) advantage of TEVAR at teaching (81% vs
77%) and LV (81% vs 75%) hospitals (Table VII), which
was lost at later time points because patients undergoing
open repair exhibited better 5-year survivals at all hospital
types (Table VII). As such, good-risk patients should be
referred for open surgical repair to HV centers for the
best early and late patient survival.TEVAR had been associated with lower perioperative
mortality and complication risk, despite application to
older and higher-risk patients in the years after FDA
approval. Gopaldas et al,13 using NIS data, reported perio-
perative mortality of patients undergoing TEVAR similar
to that of patients undergoing open repair, despite age
differences of almost 10 years and higher Deyo comorbid-
ity scores in patients treated with TEVAR in the 2 years
after FDA approval. Similarly, Walker et al16 and Bhamidi-
pati et al17 showed similar increases in TEVAR use in
higher-risk populations within the ﬁrst 2 years after
commercial availability of stent grafts, with similar or
improved risk-adjusted mortality in patients treated with
TEVAR. Our study is the ﬁrst to show that most of these
increases in TEVAR volume have been the early and rapid
adoption of TEVAR by LV hospitals.
The combination of these data suggests application of
TEVAR to higher-risk patients at hospitals with limited
experience in the management of patients with DTA.
Despite this observation, the annual operative mortality
rates of TEVAR at LV and HV hospitals have remained
stable over time. In addition, the effect of hospital volume
seen with open repair is not observed at hospitals perform-
ing TEVAR. Our sensitivity analyses suggested that
deﬁning HV on the basis of four TEVAR procedures per
year would yield similar conclusions. Our data do show
an increased independent risk of any complication (OR,
1.5; 95% CI, 1.3-1.8; P < .01), driven mainly by cardiac
and graft complications (Table V), after TEVAR performed
at HV hospitals. Risk-adjusted analysis using all measured
and available factors suggests that other unmeasured yet
important factors are contributing to increased periopera-
tive complications at HV hospitals. Long-term survival
data, as reported here, suggest no lasting effect of the
increased perioperative complications observed at HV
hospitals because our ﬁndings show similar long-term
survival independent of hospital volume.
Our ﬁndings show that teaching status deﬁned as yes or
no by the MEDPAR data set has no independent effect on
perioperative mortality or complications after TEVAR or
open DTA repair. Our study results did show an improved
long-term survival for patients undergoing open DTA (Fig)
at nonteaching hospitals by Cox regression. This may
reﬂect careful patient selection or the effect of unmeasured
factors, such as aneurysm anatomy or clinical presentation
at nonteaching hospitals, which are not available in our
data set. Our ﬁndings may also reﬂect the effect of a system-
atic error, namely selection bias, becausew70% of hospitals
were designated as teaching hospitals and >90% of DTA
repairs are performed at teaching hospitals.
In addition, it is unclear whether a hospital’s teaching
status actually reﬂects the presence of a surgical training
program (with or without vascular fellowship) or a medical
training program, or both, which may signiﬁcantly affect
the interpretation of our results. Previous reports have
shown that teaching hospitals were associated with reduced
mortality and complication rates after complex surgical
procedures (eg, pancreatectomy, hepatectomy); however,
Table VII. Survival after open repair or thoracic endovascular aortic repair (TEVAR) by hospital type
Survival Teaching, % Nonteaching, % P Low-volume, % High-volume, % P
Open repair
1-year 77 6 1 79 6 2 .06 75 6 1 80 6 1 .0046
3-year 69 6 1 72 6 2 67 6 1 71 6 1
5-year 59 6 1 66 6 3 59 6 1 61 6 1
TEVAR
1-year 81 6 1 80 6 1 .09 81 6 1 81 6 1 .71
3-year 69 6 1 65 6 2 68 6 1 68 6 1
5-year 55 6 2 54 6 3 58 6 3 54 6 2
Fig. Kaplan-Meier survival curves are shown for patients after open descending thoracic aneurysm repair at low-
volume and high-volume hospitals.
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volume.22 Our data suggest that this is also the case for
DTA repair. Although 93% of HV hospitals were also
teaching hospitals, HV hospitals represent only 10% of all
teaching hospitals, and regression modeling noted no
signiﬁcant interaction between teaching status and hospital
volume. Deﬁnitive conclusions regarding the effect of
teaching status cannot be ascertained from our study given
these limitations; therefore, further study is warranted.
Major limitations of our study include those inherent
to large administrative data sets and data availability.
Included data are unaudited and based on hospital
discharge and procedural billing claims. Whether registered
secondary diagnoses represent preoperative conditions or
postoperative complications is unclear, and those not likely
to positively affect reimbursement might not be included in
discharge claims. The speciﬁcs of postoperative complica-
tions are ill deﬁned; for instance, although ICD-9 codesare used to report graft complications, the speciﬁcs of the
severity of the graft complication cannot be known. Simi-
larly, the ICD-9 code for renal complications may include
acute tubular necrosis, a temporary increase in creatinine,
or dialysis-dependent renal failure. Reported complications
therefore represent the spectrum of all complications under
a given subheading, and the distribution of more severe or
clinically relevant complications is unknown from these
data.
Notably absent in administrative data sets are clinical
data, such as clinical presentation, operative urgency, aneu-
rysm anatomy, procedural technical details (ie, anesthesia
type, estimated blood loss, clamp location, visceral ischemia
time, hemodynamic status, length of DTA coverage,
compliance with instructions for use, staged debranching,
and iliac conduit use), protective adjunct use (ie, cerebro-
spinal ﬂuid drainage, distal aortic perfusion, and neuromo-
nitoring), and other data that have early and late clinical
Table VIII. Multivariable predictors of increased late
mortality after open repair or thoracic endovascular aortic
repair (TEVAR)
Variable HR (95 % CI) P
Open repair
Age, per year 1.04 (1.03-1.05) <.01
Nonwhite race 1.2 (1.01-1.4) .03
COPD 1.3 (1.1-1.4) <.01
Low-volume 1.2 (1.1-1.4) <.01
Teaching hospital 1.3 (1.1-1.6) .01
Cerebrovascular disease 1.7 (1.4-2.1) <.01
Chronic kidney disease 1.7 (1.3-2.1) <.01
TEVAR
Age, per year 1.03 (1.02-1.04) <.01
COPD 1.2 (1.1-1.3) <.01
Cerebrovascular disease 1.5 (1.9-2.0) .01
Chronic kidney disease 1.9 (1.6-2.3) <.01
CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease;
HR, hazard ratio.
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Volume 58, Number 2 Patel et al 353implications. Long-term follow-up information regarding
reinterventions, aneurysm-related procedures, and the
cause of death are also unavailable, therefore limiting the
ability to accurately assess durability of aortic interventions.
Our data set was limited to the years 2004 to 2007.
Inclusion of earlier years would not have added value to
our study because TEVAR was not available for wide-
spread use before 2005. As such, patients treated before
2005 and earlier than 2004 were enrolled into ongoing
FDA-approved device trials and were subject to strict
inclusion and exclusion criteria that do not reﬂect national
practices. Inclusion of patients at later dates would have
been valuable in providing better deﬁnitions of practice
trends and outcomes. An increased number of patients in
later years would have increased the statistical power of
our study, especially when analyzing outcomes by teaching
status. Better analysis of trends in practice would have
been possible with inclusion of later years; however, the
largest changes in practice patterns noted for TEVAR
and open repair occurred in the ﬁrst 2 years after TEVAR
became commercially available. Additional years would
further deﬁne the shift of TEVAR to LV hospitals, and
perhaps an increase in TEVAR cases; however, such
changes are likely to be less signiﬁcant than presented in
this report.
Despite these limitations, the availability of a large
patient cohort and the reliability of procedural and survival
data contained within the MEDPAR data set has a distinct
advantage over other publications using the NIS data set.
Our study focused on the effect of hospital type and
volume on outcomes of intact DTA repair and shows
increasing use of TEVAR for DTA repair across all hospital
types, with the most pronounced increase in TEVAR use at
LV hospitals. Although increasing application of a new
technology at inexperienced hospitals would imply
increasing risk of complications and mortality for United
States Medicare patients, our data suggest that this is not
the case.CONCLUSIONS
There has been a dramatic shift in DTA repair away
from open repair, with increasing use of TEVAR even in
LV hospitals, wherein TEVAR has eliminated the negative
volume effect on perioperative outcomes seen with open
surgery. These data suggest open surgical repair should
be concentrated in HV centers, whereas TEVAR can be
safely performed across a spectrum of hospitals.
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